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Abstract
Background: The present study analyzed whether or not the in vitro cultivation for long periods of time of pre-isolated
Leishmania amazonensis from lesions of chronically infected BALB/c mice was able to interfere in the parasites’ infectivity
using in vivo and in vitro experiments. In addition, the proteins that presented a significant decrease or increase in their
protein expression content were identified applying a proteomic approach.
Methodology/Principal Findings: Parasites were cultured in vitro for 150 days. Aliquots were collected on the day 0 of
culture (R0), as well as after ten (R10; 50 days of culture), twenty (R20; 100 days of culture), and thirty (R30; 150 days of
culture) passages, and were used to analyze the parasites’ in vitro and in vivo infectivity, as well as to perform the proteomic
approach. Approximately 837, 967, 935, and 872 spots were found in 2-DE gels prepared from R0, R10, R20, and R30
samples, respectively. A total of 37 spots presented a significant decrease in their intensity of expression, whereas a
significant increase in protein content during cultivation could be observed for 19 proteins (both cases .2.0 folds). Some of
these identified proteins can be described, such as diagnosis and/or vaccine candidates, while others are involved in the
infectivity of Leishmania. It is interesting to note that six proteins, considered hypothetical in Leishmania, showed a
significant decrease in their expression and were also identified.
Conclusions/Significance: The present study contributes to the understanding that the cultivation of parasites over long
periods of time may well be related to the possible loss of infectivity of L. amazonensis. The identified proteins that
presented a significant decrease in their expression during cultivation, including the hypothetical, may also be related to
this loss of parasites’ infectivity, and applied in future studies, including vaccine candidates and/or immunotherapeutic
targets against leishmaniasis.
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Introduction
Leishmaniasis consists of a wide range of diseases present in 98
countries worldwide, where approximately 1.6 million cases occur
each year, with an estimated 40,000 deaths [1]. Many geographic
regions are endemic for multiple Leishmania species, which is the
case in Brazil, where the disease is caused by at least six different
species of Leishmania. Among them, Leishmania amazonensis presents
a particular importance, as it is one of the main species capable of
causing human disease with a broad spectrum of clinical
manifestations, ranging from cutaneous to visceral leishmaniasis
[2,3]. In one study, it was also observed that BALB/c mice
experimentally infected with L. amazonensis developed visceraliza-
tion of the parasites in different organs, such as the brain, liver,
spleen, and bone marrow, characterizing a diagnosis of murine
visceral leishmaniasis [4].
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It has been postulated that the in vitro maintenance of parasites
by cultivation over long periods of time may well diminish their
ability to differentiate into amastigote forms [5]. In fact, long-term
axenic cultures were one of the first empirical approaches to
efficiently identify parasite virulence genes, which later led to the
experimental development of attenuated strains [6]. Similarly, the
long-term in vitro growth of drug-resistant parasites was suggested
to mediate the loss of resistance phenotype [7]. It is well-known
that parasites can regulate their gene expression, mainly at the
post-transcriptional level; however, little is known about the
biological mechanisms and the protein expression involved in this
process [8]. In this context, the identification of proteins involved
either in the infectivity of parasites in the mammal hosts, or in
their maintenance in axenic cultures, should be considered
relevant.
The proteomic study applied to evaluate the protein expression
patterns in Leishmania offers the possibility of assigning potential
functions for proteins, including those previously identified by
genomics as hypothetical, which should be evaluated, such as
vaccine candidates, diagnostic markers, and/or immunotherapeu-
tic targets. Several studies have been published evaluating the
stage-specific expression and differentiation profiles of proteins in
different Leishmania species [9,10,11,12,13,14]. In addition, the
discovery of new proteins through proteomics has been recom-
mended as one of the main research priorities for further
development and improvement of leishmaniasis vaccines [15].
In this context, the identification of proteins involved in
parasites’ infectivity should be considered important, given that
they could be used in immunological applications to prevent the
disease. In the present study, a proteomic approach, based on two-
dimensional electrophoresis (2-DE) and mass spectrometry, was
carried out to analyze the variation of protein expression profiles
in stationary promastigotes of L. amazonensis, which were pre-
isolated from lesions of chronically infected BALB/c mice and
maintained in axenic cultures over a long period of time. The
proteins that presented significant variations in their levels during
the in vitro cultivation were identified in an attempt to select new
vaccine candidates and/or immunotherapeutic targets against
leishmaniasis. The results showed several known, as well as six
hypothetical, L. amazonensis proteins, some of which are well-
known proteins involved in the infectivity of Leishmania, while
others are described through the metabolic functions of the
parasites.
Materials and Methods
Ethics statement
Experiments were performed in compliance with the National
Guidelines of the Institutional Animal Care and Use Committee
for the Ethical Handling of Research Animals (CEUA) from the
Federal University of Minas Gerais (UFMG) (Law number 11.794,
2008), which approved this study on April 25, 2012, under
protocol number 092/2012.
Mice and parasites
Female BALB/c mice (8 weeks of age) were obtained from the
breeding facilities of the Department of Biochemistry and
Immunology, Institute of Biological Sciences, UFMG, and were
maintained under specific pathogen-free conditions. L. amazonensis
(IFLA/BR/1967/PH-8) parasites were grown at 24uC in complete
Schneider’s medium , supplemented with 20% heat-inactivated
fetal bovine serum (FBS), 20 mM L-glutamine, 200 U/ml
penicillin, 100 mg/ml streptomycin, and 50 mg/ml gentamicin, at
pH 7.4. The amastigote-like cells were obtained as described in
[16].
In vivo infection
BALB/c mice (n = 8) were infected subcutaneously in their hind
footpad with 16106 stationary promastigotes of L. amazonensis. The
course of the disease was monitored at weekly intervals by
measuring footpad thickness with a metric caliper, and expressed
as the increase in thickness of the infected footpad compared to the
non-infected footpad. At week 8 post-infection, animals were
sacrificed and their infected footpads, spleen, and liver were
harvested for parasite quantification by a limiting-dilution assay
[17]. To evaluate the in vivo infectivity of parasites in the different
collected passages, R0 and R30 samples were used to infect
BALB/c mice (n = 8, each group). The infection schedule and the
parasitological analyses were the same as described above.
Preparation of the parasites for proteomics
Parasites were collected from infected footpads of the animals (8
weeks after infection) and purified to perform the proteomic
approach. For this, parasites recovered from lesions were
homogenized and immediately washed in Schneider’s medium,
which was supplemented with 10% FBS and 1% penicillin G/
streptomycin sulfate solution, and subsequently cultured in
complete Schneider’s medium. Passages of in vitro cultures were
performed every five days, until the thirtieth passage (150 days
after). Aliquots were collected on day 0 of culture (R0, first
passage), as well as 50 (R10), 100 (R20) and 150 (R30) days after
the beginning of the cultures, and quantified for the experiments.
Evaluation of in vitro infectivity
Aliquots containing parasites of R0, R10, R20, and R30
passages were centrifuged for 10 min and 5,0006 g, at 4uC. The
supernatant was removed, and the pellet containing the parasites
was washed 3 times with sterile PBS. Murine macrophages
collected from BALB/c mice were plated on round glass coverslips
within the wells of a 24-well culture plate, at a concentration of
56105 cells per coverslip in RPMI 1640 medium, which was
Author Summary
Leishmania amazonensis can induce a diversity of clinical
manifestations in mammal hosts, including tegumentary
and visceral leishmaniasis. The present study evaluated the
variation of infectivity of L. amazonensis, which was pre-
isolated from lesions of chronically infected mice and in
vitro cultured for 150 days, in turn connecting these results
with the profile of parasite protein expression using a
proteomic approach. Parasites were recovered after the
first passage, as well as after 50, 100, and 150 days of
axenic cultures, and were subsequently evaluated. A total
of 37 proteins presented a significant decrease, whereas 19
proteins presented a significant increase in their protein
expression content in the assays (both cases .2.0 fold).
Some of the identified proteins have been reported in
prior literature, including diagnosis and/or vaccine candi-
dates for leishmaniasis, while others proved to be involved
in the infectivity of Leishmania. It is interesting to note that
proteins related to the parasites’ metabolism were also the
majority of the proteins identified in the old cultures of L.
amazonensis, suggesting a possible relation between the
metabolic state of parasites and their possible loss of
infectivity. In conclusion, the proteins identified in this
study represent a contribution to the discovery of new
vaccine candidates and/or immunotherapeutic targets
against leishmaniasis.
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supplemented with 20% FBS, 2 mM L-glutamine, 200 U/mL
penicillin G, and 100 mg/mL streptomycin sulfate, at pH 7.4.
After 2 h of incubation at 37uC in 5% CO2, stationary
promastigotes of L. amazonensis were quantified and added to the
wells (16106 and 56106, for a ratio of 1:2 or 1:10 macrophage per
parasites, respectively). The cultures were incubated for 24 h at
37uC in 5% CO2. Next, the cells were washed and stained to
determine the percentages of infected macrophages and the
number of intra-macrophage amastigotes by counting 200 cells in
triplicate [18]. An optical microscopy was also used to check the
stationary profile of all in vitro cultures, and a prior titration curve
was performed to determine the best time of infection for the
macrophages (data not shown).
Preparation of total extract of Leishmania
The total extraction of proteins of L. amazonensis was performed
following a technical protocol [19]. Briefly, 26108 stationary
promastigotes were dissolved in a DeStreak rehydratation solution,
containing phosphatases (5 mM NaF, 2 mM Na3VO4, and
50 mM Na b-glycerophosphate) and proteases (Protease Inhibitor
Cocktail; plus 1 mM PMSF) inhibitors. After homogenization,
samples were disrupted by sonication in an ice bath for 15 min by
applying a continuous pulse and centrifuged at 20,0006 g for
7 min, at 4uC. The supernatant was collected, and the protein
concentration was estimated using the Bradford method [20].
Aliquots were immediately frozen at 280uC, until use. For each
passage, cellular material was extracted from the parasites
harvested from two different animals, and two independent
culture bottles of each animal were grown separately, totaling
four individual samples.
Isoelectric focusing
The isoelectric focalization (IEF) was performed using the Ettan
IPGphor3 system. For the first-dimension electrophoresis, 650 mg
of total extracts were added to a volume of 250 mL with a
rehydration solution containing a DeStreak rehydratation solution
in 1% immobilized pH gradient buffer (IPG-buffer, pH 4–7).
Next, samples were applied to IPG strips (13 cm, pH 4–7; GE
Healthcare) for passive rehydration for 18 h at room temperature.
After gel rehydration, IEF was performed at 1,000 V for 800 V/h;
8,000 V for 11,500 V/h; holding at 8,000 V for 7,500 V/h.
SDS-PAGE
After IEF, each strip was incubated for 15 min with 1%
dithiothreitol (DTT) in the equilibrium buffer [75 mM Tris-HCl
buffer, pH 8.8; 6 M urea, 39% (v/v) glycerol, and 2% (w/v) SDS],
followed by a second incubation step for 15 min in 2.5%
iodoacetamide diluted in equilibrium buffer. IPG strips were
washed with milli-Q water, transferred to a 12% polyacrilamide,
and sealed with an agarose solution (0.5% agarose in running
buffer, containing 25 mM Tris, 192 mM glycine, and 0.1% SDS,
pH 8.3). The protein standard was purchased from BioRad (pre-
stained SDS-PAGE broad range). Electrophoresis was performed
using a SE 600 ruby standard dual cooled vertical unit system
connected to a MultiTemp III cooling bath. Proteins were
separated at 30 mA/gel.
Protein digestion, peptide extraction, and spot handling
The 2-DE gels were stained with colloidal Coomassie Brilliant
Blue G-250, following a defined technical procedure [21]. For
image analysis, 16 stained gels were scanned using an ImageS-
canner III. Analyses were carried out using ImageMaster 2D
Platinum 7.0 software. This software identifies spots on a gel image
(300 dpi) by comparing the number of pixels in the background
image to the number of pixels that make up the image of the spot
itself. The spots present in the images are differentiated from other
gels by determining the spot’s position through the manual
insertion of image markers. The parameters used for spot
detection included: minimal area of 5 pixels, with a smooth factor
of 4 and a saliency of 80. The reference gel (higher number of
spots) was used to match corresponding protein spots within
different gels. The intensity volume of individual spots was
normalized by the total intensity volume (value of the intensity
volumes obtained from all spots in the same 2-DE gel) so as to
remain relatively independent of variations due to protein loading
and staining, performed by considering the total volume of all
spots in the images. All of the spots selected by software were
checked manually. The statistical test of analysis of variance (One-
way ANOVA) was performed at a 1% statistical significance level
(P,0.01) to determine the mean values of spot intensity for each
passage (R0, R10, R20, and R30) in an attempt to determine the
significant changes among the passages. Additionally, this study
applied a cut-off of at least 2-fold of the core value of intensity of
all spots selected by the program, which were the same in each
passage. The obtained fold value was the number obtained by the
ratio between the higher and lower core values of each spot’s
passage. Spots that presented significant variations within the
passages were manually excised and destained with a solution
containing 50% methanol and 2.5% acetic acid. The proteins
were reduced in 10 mM DTT and alkylated using 50 mM
iodoacetamide. Limited protein enzymatic digestion was per-
formed with 0.4 or 0.8 mg of trypsin for larger spots. Excess
protease was removed and replaced by 25 mM ammonium
bicarbonate. Digestion was performed at 37uC for 18 h. Peptide
extraction was performed twice for 15 min, using 30 mL of a
solution containing 50% acetonitrile and 5% formic acid. The
digested samples were dried using a speed-vac.
Protein identification and database search
The identification of proteins was performed at the Mass
Spectrometry Laboratory of the Brazilian Biosciences National
Laboratory (LNBio, CNPEM/ABTLuS, Campinas, Sa˜o Paulo,
Brazil). This procedure was conducted using an ESI-Quad-TOF
apparatus attached to a UPLC system. The mass spectra were
processed by the Protein Lynx V 2.1 program and analyzed by the
MASCOT MS/MS Ion Search program (http://www.
matrixscience.com). The following parameters were used for this
analysis: enzyme, trypsin; allowing of up to 1 missed cleavage;
fixed modification, carbamidomethyl (C); variable modification,
oxidation (M); peptide tolerance, 60.1 Da; MS/MS tolerance,
60.1 Da; and a peptide charge of 1+, 2+, and 3+. The database
Leishmania (dated June 2012) was used for protein identification,
the records of which can be found in the NCBI concerning
Leishmania spp. (49,496 sequences; 30,861,888 residues). All data
regarding the proteins evaluated in the present study were
harvested from NCBI, UniProt, and Gene Ontology databases.
Immunoblotting 2-DE analysis
To validate the proteins identified in this study, such as the
significant decrease or increase in their expression content after
cultivation, Western blot experiments and 2-DE gel quantitation
were performed. Whole cell extracts of stationary promastigotes
and amastigotes-like forms of L. amazonensis were separated
electrophoretically from R0 and R30 passages and transferred
onto cellulose membranes (Schleicher & Schull, Dassel, Germany)
by semi-dry blotting for 2 h at 400 mA. Membranes were blocked
in 5% (w/v) low-fat dried milk diluted in TBS plus 0.05% Tween
Proteomic Approach Applied to Leishmania amazonensis
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20 for 16 h at 4uC. Next, the membranes were washed 3 times
with a solution containing TBS and 0.05% Tween 20 (TBS-T,
10 min each) and were pre-incubated with anti-a-tubulin (1:1,000
dilution), anti-HSP83 (1:1,000 dilution), anti-GRP78 (1:2,000
dilution), or anti-paraflagellar rod protein 1D (1:2,000 dilution)
antibodies for 2 h at room temperature. After, membranes were
washed 6 times with TBS-T (10 min each) and incubated with a
peroxidase-conjugated anti-rabbit IgG secondary antibody
(1:40,000 dilution) for 2 h at room temperature. After having
been washed 7 times with TBS-T (10 min each), the reaction was
processed using ECLTM Western Blotting Detection Reagent and
ImageQuant LAS4000 equipment. The Ponceau S staining of
each membrane was used as a loading control (data not shown).
The band intensity of each protein was quantified by Image J
software. The normalized values were obtained in the comparison
between R0 and R30 of each parasite stage. The experiments were
performed in triplicate, and the Student’s t-test (P,0.05) was
employed in the statistical analyses.
Statistical analysis
The statistical analysis of the in vitro and in vivo infectivity
experiments was performed using the GraphPad Prism software
(version 5.0 for Windows). The differences were evaluated by one-
way ANOVA analysis, followed by the Bonferroni’ test. Differ-
ences were considered significant when P,0.05. Statistical
analyses evaluating the intensity and variation of the protein
expression profile in the 2-DE gels and immunoblotting were also
performed, as described above. The data are representative of
three independent experiments, performed in triplicate, which
presented similar results.
Results
Evaluation of in vivo and in vitro infectivity
BALB/c mice (n = 8) subcutaneously infected with L. amazonensis
were monitored for 8 weeks by measuring the footpad thickness,
given that the footpad swelling was similar in all evaluated animals
(Figure 1A). The number of parasites recovered in the infected
footpads, spleen, and liver of the infected animals was evaluated,
and the results showed values of 8.660.5, 5.960.6, and 4.960.6
log, respectively (Figure 1B). In this context and due to the high
homogeneity of infections in the mice, represented by similar
values of footpad swelling and parasite loads, the parasites were
recovered from lesions and used in the axenic cultures to perform
the proteomic analyses of this study.
To evaluate the variation of the in vivo infectivity between the
different passages of L. amazonensis, stationary promastigotes
obtained from R0 and R30 samples were used to infect BALB/c
mice (n = 8 per group, with 16106 stationary promastigotes
injected in each mouse). Animals infected with R30, as compared
to the animals infected with R0, presented a significantly lower
edema in the infected footpads at 8 weeks after infection
(Figure 1C). The lower lesion size observed in the R30 group,
when compared to the values obtained in the R0 group, was
related to the lower parasite load observed when evaluating the
infected footpads, spleen, and liver of these animals (Figure 1D).
For the evaluation of the in vitro infectivity, stationary
promastigotes recovered in all passages (R0, R10, R20, and
R30) were quantified and employed in the experiments. It could
be observed that by using 2 parasites to infect 1 macrophage,
parasites obtained from the R0 passage presented an infection
average of 65.161.5% and a number of amastigotes per
macrophage of 2.260.1. By contrast, using the R30 sample, the
infection average was 14.962.3% and the number of amastigotes
per macrophage was 0.560.1. When 10 parasites were used to
infect 1 macrophage, the infection average of the R0 group was
96.962.6% and the number of amastigotes per macrophage was
7.460.4. On the other hand, using parasites from the R30 group,
the infection average was 59.562.2% and the number of
amastigotes per macrophage was 3.860.4 (Table 1).
Analyses of protein expression in Leishmania
amazonensis
Electrofocusing was performed using 13 cm pH 4–7 IPG strips
after having investigated the best strip to isolate the total extracts.
Strips of 13 cm were chosen because they provide a better range of
separation of proteins by their pI without the gels becoming
difficult to handling. Two ranges of pH were evaluated: 3–10 and
4–7. This study opted for a narrower pH range, given that most of
the identified spots were located in this region. Although some
spots located outside the pH 4–7 have been missed, the most spots
were obtained within of this range due a better separation. After 2-
DE gels had been applied, approximately 837 spots were found in
the R0 sample, while 967, 935, and 872 spots were identified in
the R10, R20, and R30 samples, respectively. Figure 2 is
representative of the gels obtained in each condition. The 2-DE
profiles and the number of observed spots in the different passages
were reproducible in terms of both the total number of protein
spots and their relative positions and intensities in four 2-DE gels
performed for each passage (data not shown). After 2-DE analysis,
315 spots, which presented a significant variation in their
intensities, were selected for identification by mass spectrometry.
From all these spots, 258 were identified as proteins, and 164
unique proteins were identified. Of these, 58 proteins showed that
the intensity of their corresponding spots either increased (19 spots)
or decreased (37 spots) during the passages from R0 to R30,
always maintaining a 2-fold minimal variation. It is also important
to report that, upon performing the in vitro infection experiments, a
stabilization of the infectivity could be observed between the R20
and R30 samples (Table 1).
Identification of proteins of interest
Among the 37 proteins that presented a significant decrease in
their content during the axenic passages, six were hypothetical,
while another 31 were known proteins, like described in Table 2
[22–52]. Some of these proteins present biological functions
described in prior literature, such as tryparedoxin peroxidase
[25], metallo-peptidases [29], heat shock protein HSP70 [33],
and protein disulfide isomerase [48], all of which are involved
with the parasites’ infectivity. Possible targets for therapeutic
interventions, such as S-adenosylmethionine synthetase [47];
proteins identified as diagnosis candidates, such as acidic
ribosomal protein P2; and vaccine candidates, such as the
eukaryotic initiation factor 4A [34] and thiol-dependent reduc-
tase 1 [52], were also identified. Proteins involved in the flagellum
motility in Leishmania, such as a small myristoylated protein [22],
and others related to metabolic functions, such as aldehyde
dehydrogenase [28], were also identified. Evaluating the proteins
that presented a significant increase in their content, including
one hypothetical and 18 known proteins, could be identified.
Data are showed in Table 3 [53–70]. In relation to known
proteins, the majority are commonly involved in the parasites’
metabolism, such as nucleosome assembly proteins [57], 6-
phosphogluconolactonase [62], and rieske iron sulfur proteins
[66], while others, such as mannose-1-phosphate guanyltransfer-
ase [56] and short chain dehydrogenase [65], have been
employed as candidates for immunotherapeutic targets.
Proteomic Approach Applied to Leishmania amazonensis
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Immunoblotting validation
Some of the identified proteins that presented a significant
increase or decrease in their contents in the axenic cultures were
used to validate the results found in this study. In this context, two
of them presenting a significant decrease in their expression
content, namely a-tubulin and paraflagellar rod protein 1D, and
two of them, which presented an increase in their expression,
namely HSP83 and GRP78, were used in the Western blot
Figure 1. Infection of BALB/c mice. Mice (n = 8) were infected subcutaneously with 16106 stationary promastigotes of Leishmania amazonensis.
Lesion development in the infected footpads was monitored weekly, up to 8 weeks after infection. Mean 6 standard deviation (SD) are shown in (A).
Parasite load in the infected footpads, spleen, and liver was analyzed in all animals (B). Other mice (n = 8, per group) were subcutaneously infected
with 16106 stationary promastigotes of L. amazonensis obtained from R0 or R30 passages, and the lesion development was monitored up to 8 weeks
after infection. Mean 6 SD of the groups are shown (C). The parasite load in the infected footpads, spleen, and liver was also evaluated in these
groups (D). The experiments were repeated three times, and presented similar results. *Significant difference between the R0 and R30 groups (P,
0.05).
doi:10.1371/journal.pntd.0002764.g001
Table 1. Evaluation of in vitro infection.
Ratio Percentage of infected macrophages
R0 R10 R20 R30
1:2 65.161.5 37.863.2 19.263.6 14.962.3
1:10 96.962.6 82.861.4 64.162.5 59.562.2
Ratio Number of amastigotes per macrophage
R0 R10 R20 R30
1:2 2.260.1 1.660.1 0.760.2 0.560.1
1:10 7.460.4 5.260.8 4.360.2 3.860.4
Murine macrophages (56105 cells) were infected with stationary promastigotes of L. amazonensis (16106 and 56106, by a ratio of 1:2 or 1:10 macrophage per parasites,
respectively) and the cultures were incubated for 24 h at 37uC, 5% CO2. Next, free parasites were removed and the percentage of infected cells and the number of
amastigotes per macrophage in each passage (R0, R10, R20, and R30) were analyzed by counting 200 cells in triplicate. Mean 6 SD is shown. Data shown are
representative of three separate experiments, performed in triplicate, which presented similar results.
doi:10.1371/journal.pntd.0002764.t001
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experiments (Figure 3). When promastigote extracts were
employed, the selected proteins showed a variation that runs in
line with the results obtained in the 2-DE gels. In addition, the
decrease in the level of a-tubulin and paraflagellar rod protein 1D
detected in the promastigote forms are also maintained when the
R30 forms are axenically derived into the amastigote stage of the
parasite.
Discussion
Leishmania amazonensis is a member of the Leishmania mexicana
complex, and it is the etiological agent for a broad spectrum of
disease in South American countries [5]. The mechanisms of in vivo
persistence are of particular interest to this parasite species, given
that several lines indicate that L. amazonensis, when compared to
other Leishmania species, is particularly adept at surviving attacks
from intracellular killing mechanisms [5,14]. Taking this into
account, the present study applied a proteomic approach to
analyze the variation of the protein expression profile from L.
amazonensis, which was pre-isolated from lesions of chronically
infected BALB/c mice and maintained in in vitro cultures over a
long period of time. The purpose of this study was to verify
whether or not the in vitro cultivation, performed over a 150-day
period, could in fact decrease the parasites’ infectivity, as well as to
identify proteins that could present a relation with a possible loss of
infectivity in L. amazonensis.
Studies have shown that the maintenance of Leishmania in axenic
cultures over long periods of time constitutes a relevant factor in
the reduction of infectivity in L. infantum [71] and L. major [72]. In
one study, the loss of infectivity in L. infantum was related to the
maintenance of the parasites after 105 days of successive in vitro
passages [73]. Proteomic analyses have been employed successfully
to identify proteins expressed in both promastigote and amastigote
stages of Leishmania spp., as well as to evaluate the stage-specific
proteins and protein expression profile in the parasites
[8,11,74,75,76,77]. In the present study, proteins that presented
a significant variation in their content, observed using 2-DE gels
and analyzed by bioinformatics programs, were identified in an
attempt to select possible targets for future immunological
interventions in leishmaniasis. For this, stationary promastigotes
were used in the same concentration in all passages so as to
perform the experiments properly. In general, an increase of
Leishmania promastigote infectivity can also be observed when
parasites pass from the logarithmic phase (days 1–3) to the
stationary phase (days 4–6) of their growth cycle in in vitro cultures
[78,79,80,81]. In the present study, it could be observed that the
percentage of the stationary promastigotes found in all cultures
was homogeneous, suggesting that the changes found in the
protein expression profile and in the infectivity values of the
parasites submitted to axenic cultures, could not only be associated
with or depend on the reduction in the number of infective
promastigotes present in the in vitro cultures.
Another important aspect here was the reduction in the in vitro
and in vivo infectivity observed from R0 to R30 samples. In the in
vitro experiments performed using murine macrophages, in
addition to a significant decrease found in the percentage of
infected macrophages, a marked reduction in the number of
intracellular amastigotes could be observed. Evaluating in vitro
cultures performed up to 300 days after infection (R60), as
compared to R30, no significant difference was found in the
percentage of infected macrophages, and in the number of intra-
macrophage amastigotes (data not shown). In addition, when R0
and R30 cultures were used to infect BALB/c mice, it could be
observed that animals infected with R0 developed a more
progressive disease than did those infected with the R30 sample,
confirming the results obtained from in vitro experiments, though
no significant difference could be observed between R20 and R30
in the infectivity experiments. Furthermore, the present study’s
data are in accordance with Moreira et al. (2012), which showed
that L. infantum promastigotes present a significant loss of their
Figure 2. Two-dimensional profiles of cultures from Leishmania amazonensis. The 2-DE gels were obtained after the separation of stationary
promastigotes extracts (R0, R10, R20, and R30 passages; 650 mg of each extract) by 2-DE (first dimension: IEF pH range 4–7; second dimension: 12%
SDS-PAGE) and staining with colloidal Coomassie Brilliant Blue G-250. The gel fragments in the lower portion of the figures represent evaluated
amplifications (see within the dotted lines). 2-DE gels of each passage were derived from four independent protein preparations of each passage.
One representative preparation of each sample is showed in this study.
doi:10.1371/journal.pntd.0002764.g002
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infectivity after 100 days of in vitro cultures, suggesting that this
condition may well be related to specific modifications in the
protein differentiation content of parasites [73].
In relation to the identified proteins that presented a
decreased expression from R0 to R30, several had already
been described in other published studies, such as proteins
involved in the infectivity of Leishmania or in other parasite
species. For example, peroxidoxin is a protein expressed in the
endoplasmic reticulum of Trypanosomatides and is involved in
cellular resistance to reactive oxygen species [82], been also a
virulence factor described in Trypanosoma cruzi [83]. The malic
enzyme is involved in the virulence of Xanthomonas campestris
[84], while aldehyde dehydrogenase acts in the protection of
mammal cells against damage evoked by osmotic and saline
stress [85]. S-adenosylmethionine synthetase in L. panamensis
[86] and L. major [87] is related to drug resistance. Enolase is a
membrane protein that plays a role in the infectivity of
Leishmania, as it is involved in the interaction between the
parasites and host cells [88]. The carboxypeptidase family
(M32) has also been identified as a virulence factor in T. cruzi
[89] and operates in the catabolism of peptides, favoring the
growth and multiplication of parasites [90]. Phosphatase 2C is
considered a virulence factor in Toxoplasma gondii [91], while
tryparedoxin peroxidase in L. donovani is involved in drug
resistance [92].
Evaluating the databases of proteins that presented an increased
expression from R0 to R30, most present metabolic functions
described in prior literature, such as those related to cellular stress,
recovery of improperly folded proteins, and the restoration of core
functions. In this context, phosphatase 1 guanyltransferase
mannose is involved in oxidative stress in yeast [93], while
isocitrate dehydrogenase is involved in cellular stress in Cryptococcus
neoformans [94]. The glucose regulated protein 78 kDa is a
membrane protein that is up-regulated in conditions of cellular
stress and that can lead to cell cycle arrest [95]. The protein
complex Hs1VU-like proteolytic subunit is a peptidase that is over-
expressed and correlated to the accumulation of improperly folded
proteins within the cells [96]. Calreticulin is involved in cellular
processes related to protein folding, calcium homeostasis, apop-
tosis, and cell differentiation [97].
Western blot assays with four identified proteins were
performed to validate 2-DE gel quantification results. When
promastigote samples were analyzed, a significant correlation
could be observed when comparing the two techniques used for
proteins with a decreased or increased expression in aged cultures
(Figure 3). When axenic amastigote extracts were employed for
Western blots, a decrease in the level of a-tubulin and paraflagellar
rod protein 1D observed in the 2-DE was also detected.
Unfortunately, the lack of signs when antibodies against HSP83
and GRP78 were employed made it impossible to confirm
whether or not the increase in protein expression associated with
the loss of infectivity is maintained in the amastigote forms.
In conclusion, the data presented in the present study could
contribute to a better understanding of the biological processes
involved in a possible loss of infectivity of L. amazonensis when
submitted to in vitro cultures over a long period of time, as
described for other Leishmania species. Furthermore, the identified
proteins presenting a significant decrease in their protein content
during cultivation, including the hypothetical, should be evaluated
in future studies, including vaccine candidates and/or immuno-
therapeutic targets against leishmaniasis. Additional studies are
warranted in an attempt to address the major concern that
identified proteins are indeed involved in the possible loss of
virulence in the parasites cultured over long periods of time.
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Figure 3. Immunoblotting validation of some proteins in Leishmania amazonensis. Representative immunoblotting of some proteins that
presented a significant decrease or increase in their expression content between R0 and R30 passages, using promastigote and amastigotes-like
forms of L. amazonensis, are shown here. For each protein [a-tubulin, in A; paraflagellar rod protein 1D, in B; glucose-regulated protein 78 (GRP78) in
C, and heat shock protein 83 (HSP83), in D], this image presents one example of correspondent 2-DE spot of promastigote form obtained from R0 or
R30 passages. The antibodies used to validate each spot are described in the material and methods section. Asterisks represent the comparison
between the expression of the protein in the R0 condition in relation to the R30 sample in each parasite stage, applying the Student’s t-test (P,0.05),
and the numbers represent the relative variation of each protein in comparison to R0 of each parasite stage. All experiments were performed in
triplicate.
doi:10.1371/journal.pntd.0002764.g003
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